Clinical trials: Trop2
Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
Background: Small-cell lung cancer (SCLC) is the most deadly form of lung cancer. It kills at least 250,000 worldwide each year.
- Conditions
- Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma
- Trial name
- NCT07328490
- Testing
- Tarlatamab, Sacituzumab Govitecan
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
NSCLC Stage IV, EGFR Gene Mutation
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.
- Trial name
- TROP-LUNG (NCT07548060)
- Testing
- sacituzumab tirumotecan
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Solid Tumors
A Phase I Study of JS108 in Patients With Advanced Solid Tumors
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, PK profile and efficacy of JS108 for patients with advanced solid tumors.
- Trial name
- NCT04601285
- Testing
- JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Advanced/ Metastatic Solid Tumors
A Study of FDA018-ADC in Patients With Advanced Solid Tumors
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA018-ADC in patients with advanced/metastatic solid tumors.
- Trial name
- NCT05174637
- Testing
- FDA018-ADC
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Cervical Cancer
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body.
- Trial name
- NCT07216703
- Testing
- Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab
- Where
- 182 sites in United States, Argentina and 26 more
- Volunteers
- 1,023 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer, Metastatic
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
The goal of this clinical research study is to study the recommended dose of TROP2 CAR/IL-15 TGFBR2 KO NK cells that can be given intraperitoneally (infused directly into the stomach area) to participants with adenocarcinoma of…
- Trial name
- NCT07509008
- Testing
- TGFBR2 KO CAR27/IL-15 NK cells, Rimiducid (AP1903), Fludarabine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer, Ovarian Cancer
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
To find the recommended dose of TROP2- CAR-NK given intraperitoneally (directly into the abdominal cavity) to patients with highgrade serous ovarian cancer that has not responded to previous treatment or is resistant to treatment.
- Conditions
- Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma
- Trial name
- NCT05922930
- Testing
- TROP2-CAR-NK, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
NSCLC, Trop2
PET/CT for Trop2 ADC Response Evaluation NSCLC
To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in NSCLC patients.
- Conditions
- NSCLC, Trop2, PET/CT
- Trial name
- NCT07151898
- Testing
- 68Ga-MY6349 PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
NMIBC
Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer
Research Objective Taking Trop2, a specific target of bladder urothelial carcinoma, as the research basis, this study adopts a Trop2-targeted near-infrared (NIR) fluorescent probe combined with an intravesical rapid incubation…
- Trial name
- NCT07800507
- Testing
- TTP-ICG NIR fluorescent diagnostic agent
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yunnan Cancer Hospital
Breast Cancer
99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer
Human trophoblast cell-surface glycoprotein antigen 2 (Trop2) is a membrane surface receptor that plays an important role in the occurrence and development of tumors.
- Trial name
- NCT06104085
- Testing
- 99mTc-MY6349 SPECT/CT scan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Positron-Emission Tomography, Neoplasms
Clinical Study of TROP-2 PET/CT for Noninvasive Diagnosis of Solid Tumors
This study will investigate the safety and preliminary diagnostic efficacy of [68Ga]Ga-NOTA-T4 or [18F]AlF-RESCA-T4 in pancreatic cancer, breast cancer, head and neck cancer, lung cancers and other types of solid tumors.
- Trial name
- NCT06203574
- Testing
- [68Ga]Ga-NOTA-T4 or [18F]AlF-RESCA-T4
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
Lung Cancer
TROP2 NMR Concordance Study
This is a two-stage, multi-center study to compare concordance of Local solution and Mixed solution with a Reference solution in testing TROP2 NMR in untreated advanced NSCLC patients, as well as clinical application and…
- Trial name
- NCT07624318
- Testing
- Reference solution, Mixed solution, Local solution
- Where
- 4 sites in China
- Volunteers
- 3,400 people
- Sponsor
- AstraZeneca
Solid Tumor, Trop2
68Ga-MY6349 PET/CT in Solid Tumors
The objective of the study is to construct a noninvasive approach 68Ga-MY6349 PET/CT to detect the Trop-2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from Trop-2 PET/CT.
- Conditions
- Solid Tumor, Trop2, PET/CT
- Trial name
- NCT07046702
- Testing
- 68Ga-MY6349
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Breast Cancer, Brain Metastases From Breast Cancer
Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
The goal of this real-world study (RWS) is to evaluate the effectiveness of Trop-2 ADC (sacituzumab govitecan) in treating breast cancer patients with brain metastases, and to understand the safety profile of this drug in real…
- Conditions
- Breast Cancer, Brain Metastases From Breast Cancer, Trop2
- Trial name
- NCT07251868
- Testing
- Sacituzumab Govitecan (SG)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Cancer Hospital & Institute
Bladder Cancer (BC), Urothelial Carcinoma (UC)
Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples
Up to 30% of non-muscle-invasive bladder cancer (NMIBC) lesions may be missed by standard white-light cystoscopy, resulting in high tumor recurrence rate. This is a single-center, single-arm, phase 2 prospective study.
- Trial name
- NCT07848854
- Testing
- TTP-ICG fluorescent probe
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yunnan Cancer Hospital
Oral Squamous Cell Carcinoma (OSCC), Diagnosis
Trop2-targeting NIR-II Molecular Probe for Precision Diagnosis of Oral Cancer
Given the morphological and clinical similarities between certain oral malignant neoplasms and benign conditions such as oral ulcerations or inflammatory lesions, the potential for misdiagnosis is significant.
- Trial name
- NCT07794813
- Testing
- TTP-ICG incubation solution
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yunnan Cancer Hospital
Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR…
- Trial name
- NCT06074588
- Testing
- Sacituzumab tirumotecan, Docetaxel, Pemetrexed
- Where
- 195 sites in United States, Australia and 23 more
- Volunteers
- 556 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with…
- Trial name
- NCT05629585
- Testing
- Dato-DXd, Durvalumab, Capecitabine
- Where
- 276 sites in United States, Belgium and 15 more
- Volunteers
- 1,174 people
- Sponsor
- AstraZeneca
Epithelial Ovarian Cancer, Fallopian Tube Cancers
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
To observe the efficacy and safety of IMMU-132 in patients with advanced or recurrent ovarian cancer with high TROP-2 expression in tumor tissue, who have failed standard therapy or are unable to receive standard treatment.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary, Primary Peritoneal Carcinoma
- Trial name
- NCT07674615
- Testing
- Sacituzumab govitecan monotherapy
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Research purposes: the research design in the late more than 2 lines TNBC prospective, multicenter, cohort study, respectively to observe Trop2 - ADC joint PD - 1 single or combined anti-angiogenesis drugs (macromolecular single…
- Trial name
- NCT06878625
- Testing
- Sacituzumab Govitecan combined with Toripalimab, Sacituzumab govitecan combined with anti-angiogenesis
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital